Abstract
Several groups have published flow cytometry scores useful for the diagnosis or prognosis of myelodysplastic syndromes (MDS), mainly based on the detection of immunophenotypic abnormalities in the maturation of granulocytic/monocytic and lymphoid lineages. As anemia is the most frequent symptom of early MDS, the aim of this study was to identify markers of dyserythropoiesis relevant for the diagnosis of MDS analyzed by selecting erythroblasts in a whole no-lysis bone marrow strategy by using a nuclear dye. This prospective study included 163 patients, including 126 with cytopenias leading to MDS suspicion and 46 controls without MDS. In a learning cohort of 53 unequivocal MDS with specific markers, there was a significant difference between the coefficients of variation of mean fluorescence intensities of CD71 and CD36 in MDS patients compared with controls. These two parameters and the hemoglobin level were used to build a RED-score strongly suggestive of MDS if ⩾3. Using the RED-score in the whole cohort, 80% of MDS or non-MDS patients were correctly classified. When combined with the flow score described by Ogata et al., this strategy allowed to reach a very high sensitivity of 88% of patients correctly classified.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
WHO. Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn International Agency for Research on Cancer. IARC): Lyon, France, 2008.
Valent P, Bain BJ, Bennett JM, Wimazal F, Sperr WR, Mufti G et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res 2012; 36: 1–5.
Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26: 1730–1741.
van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS et al. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 2013; 54: 472–475.
Maynadie M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002; 100: 2349–2356.
Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979–987.
Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005; 19: 776–783.
Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 2006; 20: 549–555.
Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores-Montero J et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry 2010; 78: 154–168.
Xu F, Wu L, He Q, Zhang Z, Chang C, Li X . Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes. Intern Med J 2012; 42: 401–411.
Chopra A, Pati H, Mahapatra M, Mishra P, Seth T, Kumar S et al. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches. Ann Hematol 2012; 91: 1351–1362.
Allan RW, Ansari-Lari MA, Jordan S . DRAQ5-based, no-lyse, no-wash bone marrow aspirate evaluation by flow cytometry. Am J Clin Pathol 2008; 129: 706–713.
Bjornsson S, Wahlstrom S, Norstrom E, Bernevi I, O'Neill U, Johansson E et al. Total nucleated cell differential for blood and bone marrow using a single tube in a five-color flow cytometer. Cytometry 2008; 74: 91–103.
Edward R . Use of DNA-specific anthraquinone dyes to directly reveal cytoplasmic and nuclear boundaries in live and fixed cells. Mol Cells 2009; 27: 391–396.
Sackett DL, Haynes RB . The architecture of diagnostic research. BMJ 2002; 324: 539–541.
Holdrinet RS, von Egmond J, Wessels JM, Haanen C . A method for quantification of peripheral blood admixture in bone marrow aspirates. Exp Hematol 1980; 8: 103–107.
Ogata K, Della Porta MG, Malcovati L, Picone C, Yokose N, Matsuda A et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009; 94: 1066–1074.
Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica 2012; 97: 1209–1217.
Mitelman F . ISCN: An international system for human genetic nomenclature. S. Karger: Basel, Switzerland, 2013.
Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013; 121: 2186–2198.
Youden WJ . Index for rating diagnostic tests. Cancer 1950; 3: 32–35.
Hosmer D, Lemeshow S . Applied Logistic Regression. John Wiley & Sons Inc: New York, NY, USA, 1989.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.
Kern W, Haferlach C, Schnittger S, Alpermann T, Haferlach T . Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. Haematologica 2013; 98: 201–207.
Acknowledgements
The authors thank Catherine Gicquel, Laurence Marnet, Loetitia Rhino, Benjamin Bague and Bruno Montout from the flow cytometry team for technical assistance.
Author Contributions
SM, NC and CD performed the flow cytometric experiments and analyzed the data, AR performed the statistical analysis, IRW performed the cytogenetics, OK performed and analyzed the molecular experiments, SP and FD helped for constituting the cohort of patients and provided patient samples, CL, MCB and MF co-wrote the paper, VB designed the study, analyzed the data and co-wrote the paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Mathis, S., Chapuis, N., Debord, C. et al. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia 27, 1981–1987 (2013). https://doi.org/10.1038/leu.2013.178
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.178
Keywords
This article is cited by
-
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms
Leukemia (2024)
-
CD36 relative mean fluorescence intensity of CD105+ nucleated erythroid cells can be used to differentiate myelodysplastic syndrome from megaloblastic anemia
Scientific Reports (2023)
-
Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile
Annals of Hematology (2023)
-
CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
Leukemia (2023)
-
Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria
Current Hematologic Malignancy Reports (2018)